Achiko

19/04/2023

Achiko AG Company Update

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

29/03/2023

https://getpocket.com/collections/long-covid?utm_source=pocket-newtab

Three years on, we are still only beginning to understand one of the most mysterious and enduring challenges of the pandemic.

01/02/2023

https://www.abc.net.au/news/2023-01-31/covid-19-rapid-antigen-tests-study-inconsistent-results/101911162

Researchers analysed 10 brands of rapid antigen tests and found only two were able to detect low concentrations of the COVID-19 virus.

24/01/2023

https://www.nytimes.com/2023/01/24/health/long-covid-work.html?smid=li-share

An analysis of workers’ compensation claims in New York found that 71 percent of claimants with long Covid needed continuing medical treatment or were unable to work for six months or more.

14/01/2023

https://www.nature.com/articles/s41579-022-00846-2

Long COVID is an often debilitating illness of severe symptoms that can develop during or following COVID-19. In this Review, Davis, McCorkell, Vogel and Topol explore our knowledge of long COVID and highlight key findings, including potential mechanisms, the overlap with other conditions and potent...

13/01/2023

COVID-19 may no longer be a pandemic, but the disease likely reduced the availability of the US workforce by as much as 2.6 percent in 2022—a burden on productivity that could last for years.

04/01/2023

https://www.harvardmagazine.com/2022/12/covid-reinfection

Emerging evidence on severe complications

03/01/2023

https://neurosciencenews.com/covid19-brain-tissue-22153/

Autopsy tissue samples of 44 people who died of COVID-19 showed SAR-CoV-2, the virus responsible for coronavirus, spread throughout the body and to the brain, with traces of the virus lingering for 8 months.

27/12/2022

https://fortune.com/well/2022/12/26/is-long-covid-chronic-fatigue-syndrome-myalgic-encephalomyelitis/

“Long COVID” in some may not be an entirely new entity, researchers say.

21/12/2022

As Achiko is proceeding to sales and is currently going through external validation, we are proud to report that early results indicate that AptameX™ Gen 2 Covid-19 rapid calibration shows
a strong performance against other forms of testing.

“The price versus performance, user friendliness, and the affordability of the test compares well against other categories of testing,” said Steven Goh, CEO of Achiko AG. “As the world considers Covid-19 as endemic, the shift is now to deliver the right test for key industries such as healthcare, manufacturing, tourism and leisure, key government and other applications.”

See the test performance here:

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

20/12/2022

Achiko held its Annual General Meeting on December 20 and we are pleased to announce that all resolutions were duly passed. The Board of Directors would like to thank all those who exercised their rights as shareholders in this way. Details can be found here:

Achiko seeks to improve the lives of its customers through the use of innovative application technology.

06/12/2022

Large gaps remain, momentum has stalled and inequality is widening